GLP-1 aspiration risk under anesthesia: what the labels say

Short answer: every US label for Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Saxenda, Victoza and Trulicity has a warning titled Pulmonary Aspiration During General Anesthesia or Deep Sedation. It says these drugs delay gastric emptying, and that there have been rare postmarketing reports of pulmonary aspiration (stomach contents entering the lungs) in people on GLP-1 receptor agonists who had elective surgery or a procedure under general anesthesia or deep sedation and still had residual gastric contents after reported preoperative fasting. The labels say data are insufficient to recommend changing fasting rules or temporarily stopping the drug. They do tell patients to inform healthcare providers before any planned surgery or procedure.

On this page: US label warning · Delayed gastric emptying · Canada comparison · Severe gastroparesis · What to log

The US warning, label by label

The wording is nearly identical across the eight US labels on DailyMed (checked November 5, 2026). Each opens by saying the product delays gastric emptying, then: "There have been rare postmarketing reports of pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations." Each then states that available data are insufficient to inform recommendations to mitigate that risk, "including whether modifying preoperative fasting recommendations or temporarily discontinuing [the drug] could reduce the incidence of retained gastric contents," and instructs patients to inform healthcare providers prior to any planned surgeries or procedures if they are taking the drug.

Patient counseling on every US label adds: inform patients that the medicine may cause their stomach to empty more slowly, which may lead to complications with anesthesia or deep sedation during planned surgeries or procedures, and instruct them to tell providers beforehand. This page does not invent a hold schedule; the labels themselves say the evidence is insufficient for one.

What "delayed gastric emptying" means on the labels

Pulmonary aspiration during anesthesia is a risk when stomach contents remain and can enter the airway once protective reflexes are reduced. The GLP-1 labels tie the aspiration warning to delayed gastric emptying documented elsewhere in the same prescribing information.

• Semaglutide (Ozempic, Wegovy, Rybelsus): section 12.2 says semaglutide causes a delay of early postprandial gastric emptying (Ozempic and Rybelsus wording) or that semaglutide delays gastric emptying (Wegovy). Drug-interaction sections say that delay may affect absorption of oral medicines.
• Tirzepatide (Mounjaro, Zepbound): section 12.2 says tirzepatide delays gastric emptying, and that the delay is largest after the first dose and diminishes over time. Acetaminophen interaction studies in the labels show a reduced and delayed peak after a first tirzepatide dose, with less effect after later doses, while overall acetaminophen exposure (AUC) was not influenced.
• Dulaglutide (Trulicity): gastric motility text says dulaglutide causes a delay of gastric emptying that is dose-dependent but attenuated with dose escalation; the delay is largest after the first dose and diminishes with subsequent doses.
• Liraglutide (Victoza, Saxenda): section 12.2 says liraglutide delays gastric emptying (Victoza: thereby reducing the rate at which postprandial glucose appears in the circulation). Interaction studies report that acetaminophen overall exposure was unchanged while Cmax fell about 31% and median Tmax was delayed up to 15 minutes; the Saxenda label notes the effect on gastric emptying was equivalent at 1.8 mg and 3 mg.

Those pharmacology notes explain why residual gastric contents can appear even when someone reports following the usual fasting instructions. They are not a dosing or hold schedule.

Canada: same idea, different wording (and two older monographs)

Most Canadian product monographs place aspiration under Perioperative Considerations. Six of the eight we checked warn about aspiration with general anaesthesia or sedation and tell patients to inform their healthcare professional before such a procedure. Two older liraglutide monographs do not yet carry that section.

Zepbound's Canadian monograph is the closest match to the full US paragraph (residual gastric contents, insufficient data on fasting changes or temporary discontinuation, and an instruct-patients line). Ozempic, Wegovy, Rybelsus, Mounjaro and Trulicity use shorter "consider before such procedures" language. Saxenda and Victoza (December 9, 2022 revisions) had no aspiration or perioperative anesthesia section in the PDFs we checked; their US labels do carry section 5.9.

Severe gastroparesis: "not recommended" on the US labels

Separate from the aspiration warning, every US label says the product is not recommended in patients with severe gastroparesis. That matters for anesthesia planning because gastroparesis is itself delayed stomach emptying.

Canadian monographs generally agree: Ozempic, Rybelsus, Wegovy, Zepbound and Trulicity are not recommended in severe gastroparesis (Wegovy phrases limited experience / not recommended with a history of severe gastroparesis). Mounjaro says it has not been studied in severe gastrointestinal disease including severe gastroparesis and should be used with caution. Saxenda and Victoza say use in inflammatory bowel disease and diabetic gastroparesis has not been studied and the product should not be used in that population. For trial severe-GI rates and the October 2025 US section numbers, see GLP-1 severe gastrointestinal adverse reactions warning.

What to log and tell your surgeon or anesthetist

• That you take a GLP-1 receptor agonist (or dual GIP/GLP-1 agonist), and the brand name.
• The date and time of your last dose. The US labels ask you to inform providers before planned surgeries or procedures; a dated log makes that conversation concrete.
• The planned procedure date and whether general anesthesia or deep sedation is expected.
• Any history of gastroparesis, severe GI symptoms, or trouble emptying your stomach.
• Other oral medicines you take, since the same labels note delayed gastric emptying can affect oral-drug absorption (see the drug interactions guide for birth-control and warfarin notes).

Do not start, stop or change a GLP-1 based on this page. The labels themselves say the evidence is insufficient to recommend a temporary hold; that decision belongs to your surgical and anesthesia team.

For the other class warnings, see GLP-1 thyroid warning and contraindications, GLP-1 pancreatitis and gallbladder warnings, GLP-1 kidney and dehydration warning, GLP-1 dose schedule and GLP-1 side effects: rates and tracking.

Sources

• Ozempic prescribing information, sections 5.7, 5.10, 7.2, 12.2 and 17 (DailyMed, US)
• Wegovy prescribing information, sections 5.6, 5.10, 7.2, 12.2 and 17 (DailyMed, US)
• Rybelsus and Ozempic tablets prescribing information, sections 5.6, 5.9, 7.2, 12.2 and 17 (DailyMed, US)
• Mounjaro prescribing information, sections 5.6, 5.9, 7.2, 12.2 and 17 (DailyMed, US)
• Zepbound prescribing information, sections 5.2, 5.9, 7.2, 12.2 and 17 (DailyMed, US)
• Saxenda prescribing information, sections 5.7, 5.9, 7.1, 12.2, 12.3 and 17 (DailyMed, US)
• Victoza prescribing information, sections 5.6, 5.9, 7.1, 12.2, 12.3 and 17 (DailyMed, US)
• Trulicity prescribing information, sections 5.6, 5.9, 7.1, 12.2 and 17 (DailyMed, US)
• Ozempic product monograph, Perioperative Considerations and patient information (Novo Nordisk Canada)
• Wegovy product monograph, Perioperative Considerations and patient information (Novo Nordisk Canada)
• Rybelsus product monograph, Perioperative Considerations (Novo Nordisk Canada)
• Mounjaro product monograph, Perioperative Considerations and patient information (Eli Lilly Canada)
• Zepbound product monograph, Perioperative Considerations and patient information (Eli Lilly Canada)
• Saxenda product monograph (Novo Nordisk Canada; checked for aspiration section)
• Victoza product monograph (Novo Nordisk Canada; checked for aspiration section)
• Trulicity product monograph, Peri-Operative Considerations and patient information (Eli Lilly Canada)

This page summarizes official product labels as general information. It is not medical advice. Do not start, stop or change any medication without talking to your prescriber. Labels are updated; check the current version for your product.

Frequently asked questions